IL6 and COVID-19: Furthermore, in the multicentre, open-label, randomised, controlled COV-AID trial, no clinical benefit was observed upon blockade of the IL-6 or IL-1 pathway early in the disease course of hypoxic COVID-19 patients with evidence of systemic cytokine release syndrome44.